Samuel Kintz Sells 2,730 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 2,730 shares of Enliven Therapeutics stock in a transaction on Monday, October 7th. The shares were sold at an average price of $27.50, for a total value of $75,075.00. Following the transaction, the chief executive officer now owns 1,033,793 shares in the company, valued at $28,429,307.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Samuel Kintz also recently made the following trade(s):

• On Friday, October 4th, Samuel Kintz sold 12,206 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total value of $335,787.06.
• On Tuesday, October 1st, Samuel Kintz sold 526 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.54, for a total value of $14,486.04.
• On Monday, August 26th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.89, for a total value of $274,680.00.
• On Wednesday, July 31st, Samuel Kintz sold 2,270 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.56, for a total value of $62,561.20.
• On Thursday, July 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.92, for a total value of $299,040.00.

Enliven Therapeutics Stock Up 2.0 %

NASDAQ ELVN traded up $0.56 on Tuesday, reaching $28.01. The stock had a trading volume of 174,035 shares, compared to its average volume of 261,678. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -14.51 and a beta of 1.10. Enliven Therapeutics, Inc. has a 12-month low of $9.80 and a 12-month high of $28.51. The stock has a fifty day moving average price of $23.22 and a two-hundred day moving average price of $22.08.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.17. Sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. First Turn Management LLC bought a new position in shares of Enliven Therapeutics during the second quarter worth about $9,657,000. Janus Henderson Group PLC increased its holdings in shares of Enliven Therapeutics by 74.8% in the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after purchasing an additional 305,397 shares during the period. Marshall Wace LLP acquired a new position in Enliven Therapeutics in the second quarter worth approximately $4,489,000. Baker BROS. Advisors LP acquired a new position in Enliven Therapeutics in the first quarter worth approximately $2,020,000. Finally, Nicholas Investment Partners LP bought a new stake in Enliven Therapeutics during the second quarter worth approximately $1,310,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on ELVN. HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Finally, Robert W. Baird initiated coverage on Enliven Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price target on the stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.